Quarterly report pursuant to Section 13 or 15(d)

Clinical Trial Deposit

Clinical Trial Deposit
9 Months Ended
Mar. 31, 2021
Other Liabilities [Abstract]  
Clinical Trial Deposit


Clinical trial deposit

In October 2020, the Company announced that it had entered into a final agreement with a contract research organization (“CRO”) for the management of the Company’s registration study for glioblastoma multiforme. Under the agreement, the Company will supply the drug for the study and the CRO will manage all operational aspects of the study including site activation and patient enrollment. The Company is required to make certain payments under the agreement related to patient enrollment milestones. For the three and nine months ended March 31, 2021, the Company has recognized $1,708 and $2,958, respectively, of expenses for this study in relation to study startup and preparation for patient enrollment.

In relation to this study, the Company has made a deposit payment of $2,600 to the CRO in relation to the commencement of recruitment of patients.  It is anticipated that the deposit will be applied to future invoices, or refunded to the Company, of which $500 is anticipated to be applied in the near term and $2,100 beyond twelve months from March 31, 2021.  The Company can terminate the study at any time.  Upon termination, the Company will be liable for any payments due to the effective date of the termination as well as any non-refundable costs incurred by the CRO prior to the date of termination.